Table III.
Differences in CA19-9, HbA1c and OS in pancreatic cancer patients with and without T2D.
| Pancreatic cancer patients with T2D | Pancreatic cancer patients without T2D | ||||||
|---|---|---|---|---|---|---|---|
| Study Author, year (Ref.) | Total no. of cases | No. of patients with CA19.9 (>500) | HbA1c, % | OS (months) | No. of patients with CA19-9 (>100) | HbA1c, % | OS (months) |
| Nakai et al, 2013 (10) | 250 | 100 | 8.45+/−0.88 | 13.3+/−1.1 | 89 | 5.1+/−0.3 | 10+/−0.5 |
| Li et al, 2015 (14) | 1,328 | 335 | – | 11.7+/−1.1 | 378 | 14.2+/−1.5 | |
| Bosetti et al, 2014 (15) | 8,305 | – | – | – | |||
| Mizuno et al, 2013 (16) | 40 | – | – | – | |||
| Li et al, 2011 (17) | 2,192 | – | – | – | |||
| Oberaigner et al, 2014 (18) | 34 | – | 7.7+/−0.5 | – | |||
| Lu et al, 2015 (19) | 529 | – | 7.9+/−1 | – | 6+/−0.2 | ||
| Wang et al, 2006 (20) | 532 | – | – | – | |||
| Choi et al, 2016 (21) | 349 | 149 | – | 8.4+/−0.8 | 133 | 7.5+/−0.6 | |
| Wolpin et al, 2013 (22) | 449 | – | 5.11+/−0.24 | – | 5.09+/−0.2 | ||
| Sadr-Azodi et al, 2015 (23) | 391 | – | 7.9+/−1.1 | – | |||
CA19-9, carbohydrate antigen 19-9; OS, overall survival; T2D, type 2 diabetes mellitus.